Amarin sues looming Vascepa competitor


Amarin (AMRN) sues Omthera Pharmaceuticals, now part of AstraZeneca (AZN), claiming its cholesterol-lowering drug, Epanova, infringes on one of Vascepa's patents.

Epanova's target user population is the same as Vascepa's and GSK's Lovaza.

AZN expects the FDA to rule on Epanova's NDA by May 5.

Lovaza sales are ~$1B.

From other sites
Comments (2)
  • ralphey
    , contributor
    Comments (382) | Send Message
     
    The FDA needs an investigation. Their action towards AMRN reveals either a complete misunderstanding of the science or a more malevolent reason exists. Either way an investigation is required.

     

    They reneged on the SPA with no legal right to do so - unless the medication could cause harm .. no such evidence. They did not allow JELIS study to be presented and then requested that AMRN perform the exact same study. THey equate Vascepa with other trig lowering drugs when they dont work but refuse evidence of the exact compound when it does work !!

     

    The question is why and who is on the take - needs investigation - period
    5 Mar 2014, 12:50 PM Reply Like
  • Troiano1691
    , contributor
    Comments (5) | Send Message
     
    Indeed, ralphey but the problem is: who and where is the matador to get the sword inserted to have an effect? Our Gov. agencies are such big globs that lawsuits will drain company funds and as a foreign company they likely have to use a State Department approach which isn't much better than going through our career Reps. Maybe some larger, private organization making the case with comparison to all the other corruption within current Gov. departments might peak public interest and get the FDA scrambling to "play nice".
    5 Mar 2014, 02:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs